

In uncontrolled T2DM,
build the promise of *Live Well*, by...

Building SynerGies



In T2DM patients uncontrolled on existing therapy,




SynerGize to Maximize

Synergy to *Live Well* with hassle-free experience



Significant reductions in glycemic parameters¹



Optimization of β-cell function²



Original Article

Diabetes, Obesity and Metabolism 14: 67-76, 2012.
©2011 Blackwell Publishing Ltd

Effects of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

D. Williams-Herman, L. Xu, R. Teng, G. T. Golm, J. Johnson, M. J. Davies, K. D. Kaufman & B. J. Goldstein
Department of Clinical Research, Merck Sharp & Dohme Corp., Rahway, NJ, USA

Treatment with Sitagliptin or Metformin improved β-cell function up to 2 years²



Better tolerability and no increased risk of hypoglycemia¹

System Organ Class Preferred Term	istamet G-IR (N=190) Subjects Events n % E	Glimepiride 2 mg + Metformin 1000 mg BID (N=202) Subjects Events n % E	Overall (N=392) Subjects Events n % E
Hypoglycaemia	3 (1.6%) 5	1 (0.5%) 2	4 (1.0%) 7
Total TEAEs	25 (13.2%) 31	30 (14.9%) 36	55 (14.0%) 67
Gastrointestinal disorders	8 (4.2%) 9	20 (9.9%) 22	28 (7.1%) 31

Ref: 1. Data on File. 2. DOM 2012; 14: 67 – 76. 3. J Clin Med Res. 2014; 6(2): 127 – 132.



Build the promise of *Live Well* with Diabetes by Building SynerGies



SynerGize to Maximize

SynerG for
superior control



2.37%
HbA1c
reduction at
week 28¹

SynerG for
optimization



**Glimepiride
dose &
β-cell function^{1,2}**

SynerG for
hassle-free experience



**No increased risk
of hypoglycemia
& well-tolerated¹**



1. Data on File. 2. J Clin Med Res. 2019; 11(1): 15 - 20.

8606012 L0033920
For the use of a registered medical practitioner or a hospital or a laboratory only. Valid till Oct'24

